TMEM167A

Across TCGA pan-cancer cohorts, TMEM167A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMEM167A data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TMEM167A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM167A expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

LUAD, LSCC, and HNSC are the cancer types where TMEM167A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.171	0.738	.002	19	view →
LSCC	OS	Median	III,IV	0.716	1.000	.009	18	view →
HNSC	DFS	Tertile	All	0.801	0.553	.010	5	view →
GBM	OS	Median	All	0.596	0.443	.014	2	view →
PDAC	OS	Tertile	II,III,IV	0.587	0.261	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TMEM167A–LUAD (DFS)

Open the LUAD breakdown →